- Clinical Efficacy and Safety with Arbekacin for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
-
Kim TH, Choo EJ, Lee MS, Kim NJ, Woo JH, Ryu J, Chang MS, Yum YK
- KMID: 1620618
- Korean J Med.
- 2003 Aug;65(2):239-244.
BACKGROUND: Arbekacin was introduced to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. It is an aminoglycoside with proven in vitro activity against MRSA strains. Pharmacokinetic advantages such as concentration-dependant bactericidal activity,... -
- CITED
-
- Close
- SHARE
-
- Close
